Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Cash from Operations (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Cash from Operations readings, the most recent being 6548000.0 for Q4 2024.

  • On a quarterly basis, Cash from Operations fell 47.51% to 6548000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 28575000.0, a 56.29% decrease, with the full-year FY2025 number at 31317000.0, down 9.6% from a year prior.
  • Cash from Operations hit 6548000.0 in Q4 2024 for Unicycive Therapeutics, up from 9252000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2957000.0 in Q1 2022 to a low of 9252000.0 in Q3 2024.
  • Median Cash from Operations over the past 3 years was 4970500.0 (2023), compared with a mean of 5209083.33.
  • Biggest five-year swings in Cash from Operations: rose 27.04% in 2023 and later crashed 109.23% in 2024.
  • Unicycive Therapeutics' Cash from Operations stood at 6084000.0 in 2022, then rose by 27.04% to 4439000.0 in 2023, then tumbled by 47.51% to 6548000.0 in 2024.
  • The last three reported values for Cash from Operations were 6548000.0 (Q4 2024), 9252000.0 (Q3 2024), and 6319000.0 (Q2 2024) per Business Quant data.